Characterizing Loss of Response Occurring in a Small Number of Patients During 3 Years of Long-Term Maintenance Therapy With Baricitinib 4-Mg: Results From BRAVE-AA1 and -AA2 Trials. J of Skin 2025, 9 (1), s522. https://doi.org/10.25251/skin.9.supp.522.